Bile Acid Sequestrants Are the Primary Cholesterol Medications Not Processed by the Liver
Bile acid sequestrants (BAS)—including colesevelam, cholestyramine, and colestipol—are the cholesterol-lowering medications that are not metabolized by the liver because they are not absorbed systemically from the gastrointestinal tract. 1
Mechanism and Key Characteristics
BAS work entirely within the intestinal lumen by binding bile acids and preventing their reabsorption. This forces the liver to convert more cholesterol into bile acids, which indirectly lowers blood cholesterol levels. Critically, these agents never enter the bloodstream and therefore bypass hepatic metabolism entirely. 1, 2
Expected LDL-C Reductions:
- Colesevelam: 15% reduction as monotherapy; additional 10-16% when combined with statins 1
- Cholestyramine: 10.4% reduction versus placebo 1
- Colestipol: 16-27% reduction depending on dose (5-15g daily) 1
Clinical Advantages of Non-Hepatic Metabolism
Because BAS are not absorbed systemically:
- Safe in liver disease: No hepatotoxicity risk since they don't contact liver tissue 2
- Safe in pregnancy: Considered safe to use during pregnancy and lactation 1
- No systemic drug interactions via hepatic enzymes: Unlike statins metabolized by CYP450 enzymes 2
Important Caveats and Limitations
Gastrointestinal Side Effects:
The primary limitation is constipation, dyspepsia, and nausea due to their mechanism of action in the gut 1. These side effects limit tolerability and adherence.
Drug-Drug Interactions:
BAS decrease absorption of other oral medications. All other medications should be taken 4 hours before BAS administration. This specifically affects: 1
- Warfarin (monitor INR closely)
- Thyroid replacement therapy
- Oral contraceptives
- Cyclosporine
- Phenytoin
Contraindications:
- Triglycerides >500 mg/dL (colesevelam specifically) 1
- History of bowel obstruction
- Complete biliary obstruction (cholestyramine, colestipol) 1
Monitoring Requirements:
- Monitor triglyceride levels: BAS can paradoxically increase triglycerides and cause acute pancreatitis 1
- May cause fat-soluble vitamin deficiencies (vitamins A, D, E, K)—supplement 4 hours apart from BAS 1
Other Non-Hepatically Metabolized Options
Ezetimibe also deserves mention as it has minimal systemic absorption and works primarily in the intestinal brush border, though it does undergo some hepatic glucuronidation. It provides 15-20% LDL-C reduction with excellent tolerability. 3, 2
Cardiovascular Outcomes Evidence
Only cholestyramine has cardiovascular outcomes data among the BAS class. The LRC-CPPT trial demonstrated a 19% reduction in coronary heart disease death and/or nonfatal MI in middle-aged men with primary hypercholesterolemia. 1 Colesevelam and colestipol lack cardiovascular outcomes trials.
Practical Prescribing Approach
Choose colesevelam over older agents (cholestyramine, colestipol) when prescribing BAS because:
- Greater bile acid specificity reduces drug interactions 2
- Better gastrointestinal tolerability with less constipation 2
- Can be given as tablets (6 tablets daily) or suspension 1
Primary indications for BAS: